MOA of oral hypoglycemic agent
Oral hypoglycemics include several classes like sulfonylureas, biguanides (metformin), thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and others. The most commonly tested ones are probably metformin or sulfonylureas. For example, a classic question might be about metformin's MOA being inhibition of hepatic gluconeogenesis. Alternatively, sulfonylureas work by closing ATP-sensitive K+ channels in pancreatic beta cells.
Since the user didn't specify the options, I need to make an educated guess. Let's assume the correct answer is metformin. So the core concept would be the mechanism of action of metformin. The correct answer would be inhibition of hepatic gluconeogenesis. The other options might include things like increasing insulin secretion (sulfonylureas), increasing glucose uptake (thiazolidinediones), or others like alpha-glucosidase inhibitors.
Wait, but the user's correct answer is missing. Maybe the original question had options like A. Stimulating insulin release, B. Inhibiting hepatic gluconeogenesis (correct), C. Increasing insulin sensitivity, D. Inhibiting alpha-glucosidase. Then I need to structure the explanation accordingly. Since the user's correct answer is not given, I have to infer. Let me proceed with a common example where metformin's MOA is the correct answer.
So, the core concept is about metformin's mechanism. The correct answer explanation would involve its action on the liver. The wrong options would include mechanisms of other drugs. The clinical pearl would be that metformin is first-line for T2DM. Then, the correct answer line would be the letter corresponding to the correct option. Since the user's correct answer is not provided, I'll have to structure the explanation around a hypothetical correct answer, probably B or C. Let me check the structure again. The user wants the correct answer line as **Correct Answer: [Letter]. [Answer Text]**. Since the user's input for correct answer is empty, I need to infer. Maybe the original question had options where the correct answer is B. Inhibiting hepatic gluconeogenesis. So I'll proceed with that assumption. Let me make sure the sections are all covered and the explanation is thorough but concise. Also, keep the character count in check. Alright, putting it all together now.
**Core Concept**
Oral hypoglycemic agents (OHAs) target specific metabolic pathways to lower blood glucose. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity.
**Why the Correct Answer is Right**
Metformin inhibits mitochondrial complex I in the liver, suppressing gluconeogenesis and glycogenolysis. It also enhances glucose uptake in skeletal muscle and reduces intestinal glucose absorption. Unlike sulfonylureas, it does not stimulate insulin secretion, avoiding hypoglycemia risk.
**Why Each Wrong Option